HIV-associated sensory neuropathy: Still a problem in the post-stavudine era?

Future Virology

Volumn 7, Issue 9, 2012, Pages 849-854

  Cherry, Catherine L ^a,b   Kamerman, Peter R ^b   Bennett, David Lh ^c   Rice, Andrew Sc ^d  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

HIV; neuropathogenesis; pain; sensory neuropathy; stavudine

Indexed keywords

STAVUDINE;

ARTICLE; CHRONIC PAIN; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MORBIDITY; NEUROTOXICITY; PREVALENCE; PRIORITY JOURNAL; SENSORY NEUROPATHY;

EID: 84866640793     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.77     Document Type: Article

References (63)

1. Keswani S, Pardo C, Cherry C, Hoke A, McArthur J. HIV-associated sensory neuropathies. AIDS 16(16), 2105-2117 (2002).
2. Kamerman P, Wadley A, Cherry C. HIV-associated sensory neuropathy: risk factors and genetics. Curr. Pain Headache Rep. 16(3), 226-236 (2012).
3. Wadley A, Cherry C, Price P, Kamerman P. HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans. J. Pain Symptom. Manage. 41(4), 700-706 (2010).
4. Smyth K, Affandi J, McArthur J et al. Prevalence and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med. 8 (6), 367-373 (2007).
5. Maritz J, Benatar M, Dave J et al. HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve 41(5), 599-606 (2010).
6. Beadles W, Jahn A, Weigel R, Clutterbuck D. Peripheral neuropathy in HIV-positive patients at an antiretroviral clinic in Lilongwe, Malawi. Trop. Doct. 39(2), 78-80 (2009).
7. Cherry C, Affandi J, Imran D et al. Age and height predict neuropathy risk in HIV patients prescribed stavudine. Neurology 73(4), 315-320 (2009).
8. Meyer-Rosberg K, Kvarnström A, Kinnman E, Gordh T, Nordfors L, Kristofferson A. Peripheral neuropathic pain-a multidimensional burden for patients. Eur. J. Pain 5(4), 379-389 (2001).
9. Dworkin R, O'connor A, Audette J et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin. Proc. 85(Suppl. 3), S3-S14 (2010).
10. Finnerup N, Sindrup S, Jensen T. The evidence for pharmacological treatment of neuropathic pain. Pain 150(3), 573-581 (2010).
11. Phillips T, Cherry C, Cox S, Marshall S, Rice A. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One 5(12), e14433 (2010).
12. Clifford D, Simpson D, Brown S et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J. Acquir. Immune Defic. Syndr. 59(2), 126-133 (2012).
13. Barohn R, Gronseth G, Leforce B et al. Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals. Arch Neurol. 50, 167-170 (1993).
14. Woolley I, Faragher M, Ugoni A, Spelman D. An analysis of factors associated with HIV-related peripheral neuropathy. Neurol. Infect. Epidemiol. 2, 33-37 (1997).
15. Childs E, Lyles R, Selnes O et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 52, 607-613 (1999).
16. So Y, Holtzman D, Abrams D, Olney R. Peripheral neuropathy associated with acquired immunodeficiency syndrome-prevalence and clinical features from a population-based survey. Arch Neurol. 45(9), 945-948 (1988).
17. Ellis R, Badiee J, Vaida F et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25(14), 1747-1751 (2011).
18. Thompson M, Aberg J, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304(3), 321-333 (2010).
19. Ances B, Vaida F, Rosario D et al. Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS 23(17), 2317-2322 (2009).
20. Kumarasamy N, Venkatesh K, Cecelia A et al. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS 22(4), 227-244 (2008).
21. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. WHO, Geneva, Switzerland (2009).
22. Hahn K, Triolo A, Hauer P, McArthur J, Polydefkis M. Impaired reinnervation in HIV infection following experimental denervation. Neurology 68(16), 1251-1256 (2007).
23. Mills E, Bakanda C, Birungi J et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann. Intern. Med. 155(4), 209-216 (2011).
24. Van Sighem A, Gras L, Reiss P, Brinkman K, De Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 24(10), 1527-1535 (2010).
25. Watters M, Poff P, Shiramizu B et al. Symptomatic distal sensory polyneuropathy in HIV after age 50. Neurology 62(8), 1376-1383 (2004).
26. Morgello S, Estanislao L, Simpson D et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy. The Manhattan HIV Brain Bank. Arch Neurol. 61(4), 546-551 (2004).
27. Affandi J, Price P, Imran D, Yuhaningsih E, Djauzi S, Cherry C. Can we predict neuropathy risk before stavudine prescription in a resource limited setting? AIDS Res. Hum. Retroviruses 24(10), 1281-1284 (2008).
28. Evans S, Ellis R, Chen H et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 25(7), 919-928 (2011).
29. Nakamoto B, McMurtray A, Davis J et al. Incident neuropathy in HIV-infected patients on HAART. AIDS Res. Hum. Retroviruses 26(7), 759-765 (2010).
30. Lessells R, Mutevedzi P, Cooke G, Newell M. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa. J. Acquir. Immune Defic. Syndr. 56(3), e79-e86 (2011).
31. Gallant J, Dejesus E, Arribas J et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354, 251-260 (2006).
32. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. JAMA 292(2), 191-201 (2004).
33. Sax P, Tierney C, Collier A et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N. Engl. J. Med. 361, 2230-2240 (2009).
34. Sacktor N, Nakasujja N, Skolasky R et al. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 72(2), 165-170 (2009).
35. Forna F, Liechty C, Solberg P et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J. Acquir. Immune Defic. Syndr. 44(4), 456-462 (2007).
36. Ellis R, Rosario D, Clifford D et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 67(5), 552-558 (2010).
37. Cherry C, Affandi J, Brew B et al. Hepatitis C seropositivity is not a risk factor for sensory neuropathy among HIV patients. Neurology 74(19), 1538-1542 (2010).
38. WHO. UNAIDS World AIDS Day Report. WHO, Geneva, Switzerland (2011)
39. Cherry C, Wesselingh S, Lal L, McArthur J. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology 65(11), 1778-1781 (2005).
40. Ellis R, Marquie-Beck J, Delaney P et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann. Neurol. 64(5), 566-572 (2008).
41. Pettersen J, Jones G, Worthington C et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann. Neurol. 59(5), 816-824 (2006).
42. Cherry C, Affandi J, Rosenow A, McArthur J, Wesselingh S, Price P. Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual's NRTI-SN risk. AIDS Res. Hum. Retroviruses 24(2), 117-123 (2008).
43. Chew C, Cherry C, Imran D et al. Tumour necrosis factor haplotypes associated with sensory neuropathy in Asian and Caucasian human immunodeficiency virus patients. Tissue Antigens 77(2), 126-130 (2010).
44. Banerjee S, Mccutchan J, Ances B et al. Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy. AIDS 25(2), F1-F6 (2011).
45. Sacktor N, Nakasujja N, Skolasky R et al. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin. Infect. Dis. 49(5), 780-786 (2009).
46. Zheng W, Ouyang H, Zheng X et al. Glial TNFa in the spinal cord regulates neuropathic pain induced by HIV gp120 application in rats. Mol. Pain. 7, 40 (2011).
47. Höke A, Morris M, Haughey N. GPI-1046 protects dorsal root ganglia from gp120-induced axonal injury by modulating store-operated calcium entry. J. Peripher. Nerv. Syst. 14(1), 27-35 (2009).
48. Wallace V, Blackbeard J, Segerdahl A et al. Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. Brain 130(10), 2688-2702 (2007).
49. Wallace V, Blackbeard J, Pheby T et al. Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy. Pain 133(1-3), 47-63 (2007).
50. Attal N, Bouhassira D, Baron R et al. Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur. J. Pain 15(5), 441-443 (2011).
51. Lauria G, Hsieh S, Johansson O et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur. J. Neurol. 17(7), 903-912 (2010).
52. Maier C, Baron R, Tölle T et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 150(3), 429-450 (2010).
53. Baron R, Tölle T, Gockel U, Brosz M, Freynhagen R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia. Differences in demographic data and sensory symptoms. Pain 146(1-2), 34-40 (2009).
54. Simpson D, Schifitto G, Clifford D et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 74(5), 413-420 (2010).
55. Laast V, Shim B, Johanek L et al. Macrophage-mediated dorsal root ganglion damage precedes altered nerve conduction in SIV-infected macaques. Am. J. Pathol. 179(5), 2337-2345 (2011).
56. Kamerman P, Moss P, Weber J, Wallace V, Rice A, Huang W. Pathogenesis of HIV-associated sensory neuropathy: evidence from in vivo and in vitro experimental models. J. Peripher. Nerv. Syst. 17(1), 19-31 (2012).
57. Anderson T, Davidovich A, Arceo R, Brosnan C, Arezzo J, Schaumbureg H. Peripheral neuropathy induced by 2́,3́-dideoxycytidine. A rabbit model of 2́,3́-dideoxycytidine neurotoxicity. Lab. Invest. 66(1), 63-74 (1992).
58. Anderson T, Davidovich A, Feldman D et al. Mitochondrial schwannopathy and peripheral myelinopathy in a rabbit model of dideoxycytidine neurotoxicity. Lab. Invest. 70(5), 724-739 (1994).
59. Feldman D, Brosnan C, Anderson T. Ultrastructure of peripheral neuropathy induced in rabbits by 2́,3́-dideoxycytidine. Lab. Invest. 66(1), 75-85 (1992).
60. Wallace V, Segerdahl A, Blackbeard J, Pheby T, Rice A. Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain. Neurosci. Lett. 448(1), 153-156 (2008).
61. Maratou K, Wallace V, Hasnie F et al. Comparison of dorsal root ganglion gene expression in rat models of traumatic and HIV-associated neuropathic pain. Eur. J. Pain 13(4), 387-398 (2009).
62. Wallace V, Segerdahl A, Lambert D et al. The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. Br. J. Pharmacol. 151(7), 1117-1128 (2007).
63. Power C, Hui E, Vivithanaporn P, Acharjee S, Polyak M. Delineating HIV-associated neurocognitive disorders using transgenic models: the neuropathogenic actions of Vpr. J. Neuroimmune Pharmacol. 7(2), 319-331 (2012).